8-KItem 2.02 · Results of Operations
BIOGEN INC. (BIIB)

Biogen expects a ~$222M pre-tax acquired IPR&D/upfront & milestone charge in Q4 2025, cutting GAAP and…

Filed with the SEC on · Summarized by InvestorsBot

Biogen expects a ~$222M pre-tax acquired IPR&D/upfront & milestone charge in Q4 2025, cutting GAAP and non‑GAAP diluted EPS by ~$1.26 for the quarter. Preliminary estimates; final results subject to close procedures. $BIIB 💊📉 #Earnings #Pharma

Biogen began reporting acquired IPR&D/upfront & milestone expense as a separate line item in Q1 2025 and says it does not forecast these charges due to uncertain timing/magnitude. Q4 results unaudited and may change. $BIIB 🧾⚠️ #IPRD #Investing

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from BIOGEN INC.

Biogen ($BIIB) announced Chief Legal Officer Susan H.

8-K · March 11, 2026

Biogen ($BIIB) Board elected Dr.

8-K · February 11, 2026

Feb 11, 2026 — Biogen Board Chair Caroline Dorsa announced she will not stand for re‑election at the 2026…

8-K · February 11, 2026

Biogen ($BIIB) filed a Form 8‑K on Feb 6, 2026 furnishing a press release dated Feb 6, 2026 (Exhibit 99.1)…

8-K · February 6, 2026

Biogen ($BIIB) on Feb 6, 2026 issued a press release announcing results of operations & financial…

8-K · February 6, 2026